IGF-1 LR3 and IGF-1 DES are distinct engineered variants. A shared IGF-1 label is not enough to define the test article.
What procurement and laboratory teams should review
State complete variant name and sequence
Use the correct theoretical mass
Check assay matrix and binding-protein effects
Keep native and variant controls separated
Define the molecular form before comparing offers
Sequence alone may not fully define a peptide material. Termini, modifications, disulfide pattern, counterion, hydration state and presentation can affect molecular-weight calculations, analytical reporting, solubility and handling.
- Record sequence, termini and every modification explicitly.
- State the requested salt or counterion form.
- Treat solubility and stability as material- and condition-specific.
Questions to resolve before quotation or release
- Is the material LR3, DES or native IGF-1?
- Which evidence supports the variant?
- Does the assay address variant behavior?
Exact variant names and analytical scope are required before quotation.
Source material and further reading
This guide is informed by the following primary guidance and established technical resources. Always confirm the current version and its applicability to your material and jurisdiction.
HK PEPTIDES materials are supplied for laboratory research and documentation workflows only. They are not intended for human consumption, diagnostic use, therapeutic use, veterinary use or clinical application.